Associations between possible risk factors and Shigella infections among MSM routinely visiting the STI clinic Amsterdam, March–June 2020
| Shigella positive | P value* | OR | 95% CI | ||
| Age in years, n (%) | 16–24 | 1/67 (1.5) | 0.808 | 1 | |
| 25–34 | 6/147 (4.1) | 2.81 | 0.33 to 23.80 | ||
| 35–44 | 2/78 (2.6) | 1.74 | 0.15 to 19.59 | ||
| 45–75 | 4/97 (4.1) | 2.84 | 0.31 to 25.98 | ||
| Country of origin, n (%) | Netherlands | 8/161 (5.0) | 0.134 | 1 | |
| Other | 5/228 (2.2) | 0.43 | 0.14 to 1.34 | ||
| HIV and PrEP status, n (%) | HIV−, no PrEP use | 2/146 (1.4) | 0.038 | 1 | |
| HIV−, PrEP use | 10/151 (6.6) | 5.11 | 1.10 to 23.72 | ||
| HIV+ | 1/75 (1.3) | 0.97 | 0.09 to 10.91 | ||
| Unknown | 0/17 | 0.61 | 0.03 to 13.13 | ||
| No. of sex partners in last 6 months, n (%) | 0 or 1 | 2/35 (5.7) | 0.332 | 1 | |
| 2 or more | 11/352 (3.1) | 0.53 | 0.11 to 2.50 | ||
| Unknown | 0/2 | N.A. | |||
| NG, n (%) | Negative | 10/339 (3.0) | 0.226 | 1 | |
| Positive | 3/50 (6.0) | 2.1 | 0.56 to 7.91 | ||
| CT, n (%) | Negative | 12/354 (3.4) | 1.000 | 1 | |
| Positive | 1/35 (2.9) | 0.84 | 0.11 to 6.64 | ||
| Syphilis, n (%) | Negative | 12/384 (3.1) | 1.000 | 1 | |
| Positive | 1/5 (20) | 7.75 | 0.80 to 74.7 | ||
| Hepatitis B, n (%) | Negative | 13/388 (3.4) | 1.000 | N.A. | |
| Positive | 0/1 | N.A. | N.A. | ||
| Campylobacter, n (%) | Negative | 13/382 (3.4) | 1.000 | N.A. | |
| Positive | 0/7 | N.A. | N.A. | ||
| SARS-CoV-2, n (%) | Negative | 13/385 (3.4) | 1.000 | N.A. | |
| Positive | 0/4 | N.A. | N.A. | ||
| Anal symptoms, n (%) | None | 12/360 (3.3) | 1.000 | 1 | |
| Yes | 1/29 (3.5) | 1.04 | 0.13 to 8.26 |
Results of univariable logistic regression. Table was created by the authors.
*P values were determined excluding men with unknown values.
CT, Chlamydia trachomatis; MSM, men having sex with men; NG, Neisseria gonorrhoeae; PrEP, pre-exposure prophylaxis.;